

Policy	MM-021
Effective Date	09/01/2024
Reviewed/Revised Date	03/30/2026
Next Review Date	03/30/2027
Origination Date	06/28/2024
Originated Department	Medical Management

Infertility Testing and Treatment

Audience
Providers, Members, Brokers, MHC

Purpose
<p>Medical policies provide general support for applying Mountain Health Co-Op member policy document coverage decisions, and the member-specific benefit plan document must be referenced. The terms of the member-specific Policy document may differ from the standard benefit plan based on this medical policy. If there is a conflict between a member-specific policy document and the Mountain Health Co-Op medical policy, the document supersedes this policy. Any person(s) applying this medical policy must identify member eligibility, the member-specific policy document, and related policies or guidelines before applying this medical policy, including the existence of any state or federal guidance. Mountain Health Co-Op medical policies are designed for informational purposes only and are not an authorization, explanation of benefits, or contract. Receipt of benefits is subject to the satisfaction of all terms and conditions of the member-specific policy document coverage. Mountain Health Co-Op reserves the sole discretionary right to modify all policies and guidelines at any time.</p>

Definition
<p>Infertility is a disease defined by the failure to achieve a successful pregnancy within 12 months of regular, unprotected intercourse or therapeutic donor insemination in women younger than 35 years or within 6 months in women older than 35 years, or due to an impairment in a person’s capacity to reproduce with his or her partner, according to ACOG and the ASRM.</p> <p>Infertility affects 15% of couples, with male factor being the cause of infertility in 40-50% of couples, and 30% of all infertility being unexplained.</p>

ACOG and the ASRM recommend evaluation and treatment of any patient who by definition has infertility or is at high risk of infertility based on history. Women older than 40 years should be offered immediate evaluation and treatment. If either partner has a condition known to cause infertility, immediate evaluation should be offered.

Conception is a complicated process and depends on many factors: the production of healthy sperm by the man and healthy eggs by the woman; unblocked fallopian tubes that allow the sperm to reach the egg; the sperm's ability to fertilize the egg when they meet; the ability of the fertilized egg (embryo) to become implanted in the uterus; and sufficient embryo quality. For the pregnancy to continue to full-term, the embryo must be of viable genetic quality and the woman's hormonal and uterine structural environment adequate for its development.

Policy/Procedure

1. Mountain Health Co-Op covers certain diagnostic testing to determine the etiology of infertility in plans that have an infertility benefit.

1.1 Laboratory tests covered as part of the infertility benefit in the evaluation of infertility:

2. *Female:*

- 2.1** 17-hydroxyprogesterone
- 2.2** Anti-Muellerian hormone (AMH)
- 2.3** Dehydroepiandrosterone sulfate (DHEAS)
- 2.4** Estradiol
- 2.5** Fasting glucose
- 2.6** Follicle stimulating hormone (FSH)
- 2.7** Free and/or total testosterone
- 2.8** Human chorionic gonadotropin (HCG)
- 2.9** Luteinizing hormone (LH)
- 2.10** Progesterone challenge test

3. *Male:*

- 3.1** Follicle stimulating hormone (FSH)
- 3.2** Luteinizing hormone (LH)
- 3.3** Post-ejaculatory urinalysis
- 3.4** Semen analysis:
 - a)** Concentration
 - b)** Fructose
 - c)** leukocyte count
 - d)** microbiology
 - e)** morphology
 - f)** pH
 - g)** volume
- 3.5** Semen culture
- 3.6** Sperm antibodies

4. Procedural tests covered under the infertility benefit in the evaluation of infertility:

5. *Female:*

- 5.1** Diagnostic laparoscopy with or without chromotubation

- 5.2 Hysterosalpingography
- 5.3 Hysteroscopy
- 5.4 Salpingoscopy
- 5.5 Sonohysterography
- 5.6 Ultrasound (i.e., serial transvaginal, pelvic, ovarian)
- 6. *Male:*
 - 6.1 Scrotal exploration
 - 6.2 Scrotal ultrasound
 - 6.3 Sperm penetration assay (SPA)
 - 6.4 Testicular biopsy
 - 6.5 Transrectal ultrasound (TRUS)
 - 6.6 Vasography
 - 6.7 Y-chromosome microdeletion testing in males with non-obstructive azoospermia or severe oligospermia
- 7. **Mountain Health Co-Op does NOT cover the following tests, treatments, or procedures for infertility, as they are considered investigational/experimental.**
 - 7.1 Not covered tests, treatments, or procedures (list not all inclusive):
 - a) Antiphospholipid antibodies
 - b) Antiprothrombin antibodies
 - c) Circulating natural killer cell measurement
 - d) Clomiphene citrate challenge test (CCCT)
 - e) Co-culturing of embryos/oocytes
 - f) Computer-assisted sperm motion analysis
 - g) Cryopreservation, storage, and thawing:
 - i. Oocytes
 - ii. Ovaries
 - iii. Testicular Tissue
 - h) Cryopreservation and storage of embryos when not undergoing covered active
 - i) Infertility treatment
 - j) Direct intraperitoneal insemination
 - k) Donor charges
 - l) Embryoscope or Time-Lapse imaging of Embryos
 - m) Embryotoxicity assay
 - n) Endometrial receptivity testing
 - o) Fallopian tube sperm transfusion
 - p) Fine needle aspiration mapping
 - q) Hemizona test
 - r) Hyaluronan binding assay (HBA)
 - s) Intrafollicular insemination
 - t) IV immunoglobulins
 - u) Karyotyping for chromosomal abnormalities
 - v) Laser-assisted necrotic blastomere removal from cryopreserved embryos
 - w) Leukocyte immunization
 - x) Over-the-counter (OTC) prediction/pregnancy tests
 - y) Post-coital test
 - z) Reactive oxygen species testing (ROS)

- aa)** Receptiva (BCL6 assay) used for undiagnosed endometriosis
- bb)** Serum inhibin-B for detecting ovarian reserve
- cc)** Sperm DNA integrity testing
- dd)** Sperm precursors
- ee)** Sperm viability test (diagnostic)
- ff)** Surrogacy

8. *The following section is intended ONLY for employer groups who have elected infertility treatment coverage.*

9. Mountain Health Co-Op covers *certain* treatments for infertility as outlined below:

10. Treatments covered under the fertility benefit include:

10.1 Female:

- a)** 17-hydroxyprogesterone caproate
- b)** Artificial insemination (intrauterine)
- c)** Assisted embryo hatching
- d)** Cryopreservation of embryos
- e)** Fimbrioplasty
- f)** Fluoroscopic/hysteroscopic selective tube cannulation
- g)** Gamete intrafallopian transfer (GIFT) or pronuclear stage transfer (PROST), or natural cycle IVF
- h)** In vitro fertilization with embryo transfer (IVF-ET)
- i)** Intracytoplasmic sperm injection (ICSI)
- j)** Low tubal ovum transfer (LTOT)
- k)** Lysis of adhesions
- l)** Myomectomy
- m)** Operative hysterectomy
- n)** Ovulation induction medications
- o)** Ovulation monitoring studies
- p)** Removal of tumors and cysts
- q)** Salpingectomy
- r)** Salpingostomy
- s)** Septate uterus repair
- t)** Surgical laparoscopy
- u)** Zygote intrafallopian transfer (ZIFT)

10.2 Male:

- a)** Electroejaculation
- b)** Excision of tumors (e.g., epididymal)
- c)** Microsurgical epididymal sperm aspiration (MESA)
- d)** Orchiopexy
- e)** Percutaneous epididymal sperm aspiration (PESA)
- f)** Pharmacologic treatment of endocrinopathies:
 - i.** Androgens
 - ii.** Corticosteroids
 - iii.** human chorionic gonadotropins
 - iv.** human menopausal gonadotropin
 - v.** pulsatile gonadotropin-releasing hormone
- g)** Repair of varicocele

- h) Seminal vesicle sperm aspiration
- i) Spermatic vein ligation
- j) Testicular fine needle aspiration (TEFNA)
- k) Testicular sperm aspiration (TESA)
- l) Testicular sperm extraction (TESE)
- m) Transurethral resection of the ejaculatory ducts (TURED)
- n) Vasal sperm aspiration

11. Clinical Rationale

11.1 An infertility evaluation is usually initiated after 1 year of regular unprotected intercourse in women under age 35 and after 6 months of unprotected intercourse in women age 35 and older. However, the evaluation may be initiated sooner in women with irregular menstrual cycles or known risk factors for infertility, such as endometriosis, a history of pelvic inflammatory disease, or reproductive tract malformations.

12. Laboratory Tests for Females

12.1 For women over 35 years of age and younger women with risk factors for premature ovarian failure, testing for ovarian reserve with a day 3 FSH level is recommended. Other tests such as the clomiphene citrate challenge test (CCCT), antral follicle count, and anti-Müllerian hormone (AMH) level are utilized by specialists and in special circumstances.

13. Follicle Stimulating Hormone (FSH) and Clomiphene Citrate Challenge Test (CCCT)

13.1 Both the day 3 FSH level (where day 1 is the first day of full menstrual flow) and the CCCT, which is a provocative test for measurement of FSH, are widely used for screening ovarian reserve. The CCCT involves oral administration of 100 mg clomiphene citrate on cycle days 5-9 with measurement of day 3 and day 10 FSH levels and day 3 estradiol levels.

13.2 The basis of these tests is that women with good ovarian reserve have sufficient production of ovarian hormones from small follicles early in the menstrual cycle to maintain FSH at a low level. In contrast, women with a reduced pool of follicles and oocytes have insufficient production of ovarian hormones to provide normal inhibition of pituitary secretion of FSH, so FSH rises early in the cycle.

13.3 Meta-analyses of nonrandomized studies concluded that basal cycle day 3 FSH and the CCCT testing perform similarly for predicting ability to achieve a clinical pregnancy in women undergoing infertility treatment. With either test, a normal result is not useful in predicting fertility, but a highly abnormal result (FSH > 20 mIU/mL) suggests that pregnancy will not occur with treatment involving the woman's own oocytes.

13.4 Elevated basal estradiol levels are due to advanced premature follicle recruitment that occurs in women with poor ovarian reserve. High estradiol levels can inhibit pituitary FSH production and thus mask one of the signs of decreased ovarian reserve in perimenopausal women. Thus, measurement of both FSH and estradiol levels helps to avoid false-negative FSH testing. According to the ASRM

Clinical Practice Document, clomiphene challenge testing is not helpful to assess ovarian reserve and is not recommended.

14. Dehydroepiandrosterone Sulfate (DHEAS)

14.1 Women with signs of androgen excess or menstrual irregularity should be tested with levels of total and calculated free testosterone, as well as 17-hydroxyprogesterone and dehydroepiandrosterone sulfate levels to rule out CAH or androgen-secreting tumors.

15. Luteinizing Hormone (LH)

15.1 The luteinizing hormone (LH) is produced by the pituitary gland. In women, LH stimulates estrogen and progesterone production from the ovary. A surge of LH in the mid-menstrual cycle is responsible for ovulation, and continued LH secretion subsequently stimulates the corpus luteum to produce progesterone. Development of the ovarian follicle is largely under FSH control, and the secretion of estrogen from this follicle is dependent on FSH and LH. The granulosa cells of the ovary secrete inhibin, which plays a role in cellular differentiation.

16. Post-Coital Test

16.1 Sperm-cervical mucus interaction identifies whether the problem is in the sperm or in the cervical mucus and is assessed in vivo by the post-coital test and in vitro by the slide or capillary tube tests.

16.2 The post-coital test suffers from poor reproducibility and its positive predictive value for pregnancy is no better than 50%. Utilizing the post-coital test leads to more tests and treatments but yields no improvement in cumulative pregnancy rates.

17. Progesterone Challenge Test

17.1 This is given to see if a woman is still secreting estrogen. It consists of doses of progesterone given over a 10-day period. When the reproductive anatomy of a woman is normal, the absence or the loss of ovulation is usually caused by a hormonal condition. If estrogen is present, the progestin challenge test will then trigger a menstrual period in the woman. This situation is called ovulation, in which case estrogen levels are typically normal.

18. Laboratory Tests for Males

19. Semen Analysis

19.1 The semen analysis is the cornerstone of the assessment of the male partner of an infertile couple. In addition to the standard analysis, specialized analyses can be performed in some laboratories. The semen sample should be collected after 2-7 days of abstinence and should be submitted to the laboratory within 1 hour of collection.

19.2 The semen analysis is the cornerstone of the assessment of the male partner of an infertile couple. In addition to the standard analysis, specialized analyses can be

performed in some laboratories. The standard semen analysis consists of the following:

- a) Measurement of semen volume and pH
- b) Microscopy for debris and agglutination
- c) Assessment of sperm concentration, motility, and morphology
- d) Sperm leukocyte count
- e) Search for immature germ cells

19.3 Because of the marked inherent variability of semen analyses, at least 2 samples should be collected 1-2 weeks apart. The semen analysis should be performed using standardized methods. In addition, the laboratory should employ internal quality control measures and participate in external quality control programs.

20. Sperm Autoantibodies

20.1 Sperm autoantibodies are present in about 4%-8% of subfertile men. The presence of agglutination in the initial semen analysis suggests sperm autoimmunity; this should be confirmed by the mixed antiglobulin reaction or the immunobead test, both of which detect sperm surface antibodies. Antibodies are considered clinically important when over 50% of the spermatozoa are coated with them and when the spermatozoa fail to penetrate preovulatory human cervical mucus or demonstrate impaired fertilizing capacity. Studies suggest use of new proteomic analyses to assess such antibodies may provide a greater understanding of this disorder.

21. Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH)

21.1 In men, LH stimulates testosterone production from the interstitial cells of the testes (Leydig cells). FSH stimulates testicular growth and enhances the production of an androgen-binding protein by the Sertoli cells, which are a component of the testicular tubule necessary for sustaining the maturing sperm cell.

21.2 This androgen-binding protein causes high local concentrations of testosterone near the sperm, an essential factor in the development of normal spermatogenesis. Sertoli cells, under the influence of androgens, also secrete inhibin, a polypeptide, which may help to locally regulate spermatogenesis. Hence, maturation of spermatozoa requires FSH and LH.

22. Post-Ejaculatory Urinalysis (PEU)

22.1 This test is done to see whether or not some or all of the sperm is ejaculated backward into the bladder, a condition known as retrograde ejaculation. To perform this test, it is necessary for a man to provide a semen sample and, immediately afterwards, a urine sample. This post-ejaculatory urine is then examined for the presence of sperm.

23. Semen Culture

23.1 Semen culture is frequently performed in men whose semen samples contain inflammatory cells to diagnose bacterial contamination of the semen.

24. Procedural Tests for Females

25. Diagnostic Laparoscopy with or without Chromotubation

25.1 The diagnosis and severity of endometriosis are established by laparoscopy and biopsy using the revised American Fertility Society system, which classifies the severity of endometriosis into 4 stages: stage I (minimal), stage II (mild), stage III (moderate); and stage IV (severe). This classification system is widely used and includes visual assessment, which is subject to inter- and intra-observer error.

However, disease severity has not been shown to predict the chance of pregnancy.

25.2 Laparoscopy is indicated in women with a suspicion of endometriosis (dysmenorrhea, pelvic pain, deep dyspareunia) or pelvic adhesions/tubal disease (history of pelvic pain, complicated appendicitis, pelvic infection, pelvic surgery, or ectopic pregnancy) based on history, physical examination, or hysterosalpingogram (HSG). When laparoscopy is performed, chromotubation is also performed simultaneously to assess tubal patency and hysteroscopy to evaluate the uterine cavity. For this reason, if laparoscopy is planned, then HSG can be omitted.

25.3 The advantage of performing laparoscopy early in the evaluation of women suspected of having endometriosis or pelvic adhesions is that surgical therapy can be initiated, while avoiding potentially ineffective or unnecessary empiric medical treatment for ovulation induction. Endometriosis, if identified, can be excised or ablated at the time of the diagnostic procedure and pelvic adhesions can be lysed.

26. Endometrial Biopsy

26.1 This test is designed to evaluate the endometrial lining of the uterus and historically to obtain an objective assessment of ovulation or to rule out luteal phase defect (LPD). LPD is defined as either a short luteal phase (less than 12 days) which is the second part of the menstrual cycle after ovulation and until menstruation or inadequate progesterone production. Currently, LPD diagnosis is questionable and the practice of doing an endometrial biopsy solely to document ovulation is no longer acceptable. The most common reason for an endometrial biopsy is to rule out precancerous growth in the uterine cells called endometrial hyperplasia or endometrial cancer.

27. Hysterosalpingography

27.1 Hysterosalpingogram (HSG) is usually done in all patients to look for tubal occlusions, unless laparoscopy is planned. Either water or lipid soluble contrast media can be used. HSG also provides information about the uterine cavity. Women with abnormalities on HSG should be referred to a reproductive endocrinologist to discuss treatment options. HSG is not useful for detecting peritubal adhesions or endometriosis.

27.2 A meta-analysis of 20 studies involving 4,179 patients compared HSG and laparoscopy with chromotubation (the gold standard); the calculated sensitivity and specificity for diagnosis of tubal patency were only 65% and 83%, respectively. However, when subgroups of women undergoing HSG were analyzed, HSG appeared to have very high specificity and sensitivity for diagnosing distal tubal

occlusion or major distal tubal adhesions, but much lower specificity for diagnosing proximal tubal occlusion.

27.3 Proximal tubal occlusion on HSG often represents testing artifact due to tubal spasm or poor catheter positioning leading to unilateral tubal perfusion. Given these deficiencies, findings of proximal tubal occlusion on HSG could be confirmed by a secondary test such as a repeat HSG, fluoroscopic or hysteroscopic selective tubal perfusion, or laparoscopic chromotubation if definitive diagnosis will influence further management.

27.4 Diagnostic HSG also appears to have therapeutic effects. A systematic review of 12 randomized trials found that pregnancy rates were significantly higher in subfertile women who underwent tubal flushing with oil soluble media than in those who did not undergo HSG (OR 3.30, 95% CI 2.00-5.43), and that pregnancy rates were similar whether oil or water soluble media were used (OR 1.21, 95%CI 0.95-1.54).

28. Hysteroscopy

28.1 Uterine abnormalities such as adhesions, polyps, submucous leiomyomas and septae have been found in 10%-15% of women seeking treatment for fertility problems. Compared with HSG, hysteroscopy is recognized as the 'gold standard' test for identifying uterine abnormalities as it allows direct visualization of the uterine cavity.

28.2 Opinions differ as to whether hysteroscopy should be considered as a routine investigation in addition to HSG and laparoscopy and dye in the infertile couple. A causal relationship between leiomyoma and infertility has not been established. In women undergoing assisted reproduction, the presence of uterine leiomyoma is associated with a reduced chance of clinical pregnancy or delivery. However, the effectiveness of surgical treatment of uterine abnormalities to enhance pregnancy rates is not established.

29. Salpingoscopy

29.1 Salpingoscopy is an endoscopic technique that allows direct evaluation of the ampullary tubal mucosa at the time of laparoscopy. It has been reported that the presence of ampullary mucosal adhesions can negatively affect reproductive outcome and increase the risk of ectopic tubal pregnancy. Various studies have suggested that the extent of intra-luminal adhesions may not correlate with the nature and extent of periadnexal adhesions. Further studies on salpingoscopic and laparoscopic correlations with regard to fertility outcome have been reported in the literature. Recently microsalingoscopy has been introduced, with the number of nuclei stained by methylene blue dye employed as a prognostic factor of conception in women with infertility. As an alternative to salpingoscopy performed during laparoscopy, which requires hospitalization and general anesthesia, 2 groups have described salpingoscopy as an office procedure performed during transvaginal hydrolaparoscopy or in conjunction with fertiloscopy.

29.2 The prognostic value of salpingoscopy during operative laparoscopy for tubal factor infertility in terms of reproductive outcome has been confirmed. The prognostic significance of microsalingoscopy needs further validation in large-

scale clinical trials. Transvaginal hydrolaparoscopy and fertiloscopy appear to be an alternative to hysterosalpingography as a first line procedure to investigate female infertility.

30. Sonohysterography

30.1 Saline infusion sonohysterography refers to a procedure in which fluid is instilled into the uterine cavity transcervically to provide enhanced endometrial visualization during transvaginal ultrasound examination. The technique improves sonographic detection of endometrial pathology, such as polyps, hyperplasia, cancer, leiomyomas, and adhesions. In addition, it can help avoid invasive diagnostic procedures in some patients as well as optimize the preoperative triage process for those women who require therapeutic intervention. It is easily and rapidly performed at minimal cost, well-tolerated by patients, and is virtually devoid of complications. Saline infusion sonohysterography is useful for detecting potential anatomic causes of reduced fertility, such as submucous myomas, endometrial polyps, anomalies, and intrauterine adhesions and appears comparable to or better than hysterosalpingography (HSG) or hysteroscopy. However, an outline of the fallopian tubes (as seen with HSG) is not observed with sonohysterography. Accretion of instilled fluid in the posterior cul-de-sac is a sign of patency of at least 1 tube.

31. Ultrasound (i.e., serial transvaginal, pelvic, ovarian)

31.1 Compared with bimanual pelvic examination, transvaginal ultrasound enables pelvic anatomy to be identified with more accuracy and reliability. Ultrasound can be used in the evaluation of pelvic pathology, such as endometriosis, endometrioma, cysts, polyps, leiomyoma, adnexal and ovarian abnormality, where such abnormalities are present. The diagnostic criteria for polycystic ovaries and polycystic ovary syndrome (PCOS), in which ultrasonic parameters have an important role, have been evolving over many years, and have recently been clarified in an international consensus statement.

32. Procedural Tests for Males

33. Karyotyping for Chromosomal Abnormalities

33.1 Karyotyping as a screening test for male or female is not indicated as part of the initial evaluation because of the low incidence of abnormalities.

33.2 Karyotype and Y-chromosome microdeletion analysis should be recommended for men with primary infertility AND azoospermia or severe oligozoospermia (<5 million sperm/mL) with elevated FSH or testicular atrophy or a presumed diagnosis of impaired sperm production as the cause of azoospermia.

33.3 Karyotype may be useful in male and female patients who have failed initial treatment approaches and plan to undergo in vitro fertilization (IVF), although the cost-effectiveness of universal karyotype screening prior to IVF has not been established.

34. Scrotal Exploration

34.1 Scrotal evaluations may reveal testicular defects, obstruction, or congenital defects of vas deferens to determine the location of the obstruction and attempt to correct it. This is major surgery, with all of its risks. It is an outpatient surgery procedure usually performed under general anesthesia. The variation in cost will generally reflect the complexity of the repair and the time required to perform the operation, from 1 ½-5 hours. Before the scrotal exploration, the urologist may recommend a biopsy of the testicle as a separate procedure to determine if enough sperm are present before proceeding on to the more serious scrotal exploration. The biopsy is also an outpatient procedure that can be performed under either local or general anesthesia.

35. Scrotal Ultrasound

35.1 Ultrasound (US) is a readily available and relatively inexpensive imaging modality that can be performed on patients at any age without the need for sedation or any other pretest preparation. US examinations are safe and there is no significant biologic risk from radiation exposure. Gray-scale US provides high-resolution depiction of scrotal anatomy and Doppler technique demonstrates perfusion.

35.2 Different pathologies of the scrotum may have similar clinical presentation, such as acute scrotal pain or scrotal mass. US of the scrotum can better guide treatment by improving the definition of the scrotal pathology. For these reasons, US became the imaging modality of choice for evaluation of scrotal pathology, and, in most cases, US is the first and only imaging needed for evaluation of scrotal pathology. This test uses high-frequency sound waves to produce images inside the body. A scrotal ultrasound can help find evidence of a varicocele or obstruction of the part of the testicle that stores sperm (epididymis). A small wand is moved over the surface of the scrotum to produce images on a video screen.

36. Sperm Penetration Assay (SPA)

36.1 Originally, the SPA, also known Zona-free hamster oocyte penetration test was used primarily as a diagnostic technique for male infertility. More recently, the advent of sperm micromanipulation techniques, specifically ICSI, has changed the role of IVF and changed the role of SPA. IVF was originally developed as a treatment option for women with irreversible tubal damage, but the development of sperm micromanipulation techniques as an adjunct to IVF has now expanded the indications for IVF to those with severe male factor infertility. Thus, SPA can be used to identify those normospermic patients who would benefit from ICSI or other adjuncts to IVF. In 2001, Freeman et al. reported on the diagnostic accuracy of sperm penetration assay in predicting success of in vitro fertilization. Among 216 couples, the sperm penetration assay predicted IVF with high negative (84%) and positive (98%) predictive value, with correct prediction in 88% of cycles. While there is still concern regarding standardization of the procedure, these results suggest that the results of the SPA can be used to select patients for ICSI.

37. Testicular Biopsy

37.1 Diagnostic testicular biopsy is 1 parameter for determining the testicular histopathology pattern and apparently it is the strongest indicator to foresee the

possibility of finding sperms in the testis. Identification of the border line between normal and disturbed spermatogenesis substantiate the diagnosis of impaired male fertility. In the past, testicular biopsy was reserved for azoospermia patients with a normal-sized testis and normal findings on hormonal studies to evaluate for ductal obstruction. Azoospermic men with testicular failure (non-obstructive azoospermia) have either Sertoli cell only pattern, maturation arrest or hypospermatogenesis on testis biopsy. Until recently it was assumed that men with non-obstructive azoospermia were untreatable. The discovery that azoospermic men with germinal failure often have minute foci of spermatogenesis was observed in the early studies of quantitative analysis of spermatogenesis. However, testicular biopsy is now also an invaluable procedure for further workup of the infertile male and for therapeutic sperm retrieval in assisted reproductive techniques. One study confirms that testicular biopsy is an important tool in the investigation and the assessment of male infertility as it provides some light on the etiology as well as providing essential prognostic information of azoospermic men in Egypt. The most common finding in this series was that of normal testis denoting obstruction (24%), while among cases of functional azoospermia, Sertoli cell only (34%) and spermatogenic arrest (28%) was the most frequent.

38. Transrectal Ultrasound (TRUS)

38.1 TRUS has replaced incisional vasography as diagnostic technique of choice in the evaluation of male pelvic reproductive anatomy. This is due in part to urologist's overall familiarity with TRUS for prostate anatomy and biopsies, along with the superb visual resolution of seminal vesicle and ejaculatory duct anatomy that TRUS provides.

38.2 TRUS is commonly performed with a high resolution 6.5-7.5 MHz probe with the patient's bladder partially filled to maximize bladder, perivesical and seminal vesicle anatomy. TRUS is most commonly obtained if the diagnosis of ejaculatory duct obstruction is being considered. As such, TRUS is indicated in infertile patients with low volume azoospermia and low volume oligoasthenospermia as well in men with painful ejaculation or recurrent hematospermia. As outlined in, several characteristic TRUS findings are highly suggestive of ejaculatory duct obstruction. These findings are derived from the normal anatomical findings described in fertile men, cadavers and prostatectomy patients. It is important to remember that these findings can be unilateral or bilateral.

39. Vasography

39.1 A vasogram involves the injection of dye or contrast media into the vas deferens to determine whether a physical obstruction exists in the vas deferens, seminal vesicles or ejaculatory ducts. Although bowing to TRUS as the first line diagnostic procedure in the setting of ejaculatory duct obstruction, it remains the "gold standard" procedure for diagnosis of pelvic, inguinal or scrotal vasal obstruction. Vasography can be performed in either an antegrade (testis to prostate) or retrograde (prostate to testis) fashion, by transrectal, transperineal, transurethral or transscrotal routes. The most reliable approach is transscrotal, but this procedure is also the most invasive as it involves a vasotomy, either microsurgical or by puncture.

The risk of vasal scarring that attends this approach has led investigators to consider other, less invasive measures such as TRUS guided procedures to garner similar information.

40. Y-chromosome Microdeletion Testing in Males with Nonobstructive Azoospermia or Severe Oligospermia

40.1 Males with non-obstructive azoospermia should have genetic testing before proceeding to assisted reproductive technologies. Genetic disorders may be characterized as karyotype abnormalities. In some men, microdeletions of the Y chromosome contribute to azoospermia. Male offspring born to fathers of Y-chromosome microdeletion are expected to inherit these deletions. Counseling regarding genetic issues should be a critical part of the male evaluation.

41. Fertility Treatments for Females

42. 17-alpha-hydroxyprogesterone caproate

42.1 Weekly injections of 17 alpha-hydroxyprogesterone caproate between 16 and 36 weeks of gestation may be considered medically necessary in pregnant women with a prior history of a preterm delivery before 37 weeks gestation.

42.2 Daily vaginal progesterone suppositories 24-34 weeks gestation may be considered medically necessary in pregnant women with a prior history of preterm delivery before 37 weeks gestation, a prior cervical cerclage or a uterine anomaly.

43. Artificial Insemination (intrauterine) [IUI]

43.1 Intrauterine insemination (IUI) is a procedure in which processed and concentrated motile sperm are placed directly into the uterine cavity. IUI is useful in couples with severe sexual dysfunction since coitus can be avoided. Its advantages in cervical factor and male factor infertility are that sperm bypass potentially hostile cervical factors and the number of sperm that gain access to the uterine cavity is enhanced. In women undergoing ovulation induction, randomized trials have reported higher pregnancy rates with ovulation induction combined with IUI compared with ovulation induction alone, or with timed intercourse.

43.2 IUI is contraindicated in women with an active cervical, intrauterine, or pelvic infection. This would be in the setting of a recently documented or diagnosed infection, or if there were concern at time of IUI, such as purulent discharge from the cervix or recent exposure to a sexually transmitted disease. The cumulative pregnancy rate after IUI generally ranges from 5%-20%; the reported range varies widely and depends upon multiple factors. Lower pregnancy rates may occur when there has been a longer duration of infertility, female age is over 40 years, or in the presence of severe male factor infertility. Higher pregnancy rates have been documented when ovulation induction was combined with IUI. This increase in pregnancy rates appears to be due to an increase in the number of mature oocytes available for fertilization, but multiple gestation rates were also increased to 10%-40%.

44. Assisted Embryo Hatching

44.1 Assisted hatching is a technique performed to enhance the likelihood that the transferred embryo will implant in the uterus and establish a viable pregnancy. The technique involves in vitro disruption of the zona pellucida surrounding the embryo so that the embryo can "escape" and implant into the uterine wall. Assisted hatching has also been referred to as zona drilling and partial zonal dissolution. Assisted hatching is commonly performed as part of an IVF procedure in women over 40, who have a decreased incidence of implantation after embryo transfer, and in women with prior failed IVF cycles due to failed implantation.

45. Cryopreservation of Embryos

45.1 If there are embryos that are not needed for transfer in the current cycle, cryopreservation may be used. This is a process in which the embryos are frozen in liquid nitrogen and may be thawed for future use. A significant percentage of embryos do not survive the process of freezing and thawing, however. Cryopreservation may result in hardening of the zona pellucida which may affect hatching and implantation of blastocyst. Some embryos lose 1 or more blastomeres after thawing and are referred to as "partially damaged" embryos. While partially damaged embryos can give rise to term pregnancy, authors agree that the developmental potential of these embryos is inferior to those that are fully intact. Some authors have reported that laser-assisted removal of necrotic blastomeres from partially damaged cryopreserved embryos before embryo transfer increases embryo development potential.

45.2 Available data on the effects of cryopreservation of embryos did not indicate any apparent negative impact on perinatal outcome, early infant development or congenital malformation rate. A retrospective study compared babies (n = 283) from births from cryopreserved embryos with babies (n = 961) after conventional IVF. There was no difference in the incidence of twins, triplets, their mean gestational age, birth weight and perinatal mortality rates between the 2 groups. The incidence of major congenital malformations was significantly lower in the cryopreserved group (1%) than in the IVF group (3%). One study matched 255 children from cryopreserved embryos for maternal age, parity, single or twin pregnancy and date of delivery with 255 children born after standard IVF with fresh embryos and 252 children from spontaneous pregnancies. The incidence of major malformations and the prevalence of chronic diseases at 18 months were similar in all 3 groups.

46. Fimbrioplasty

46.1 Fimbrioplasty is performed for treatment of partial obstruction of the distal end of the fallopian tube. The tube is patent, but there are adhesive bands that surround the terminal end. The longitudinal folds of the tube are usually preserved. Fimbrioplasty involves dividing the peritoneal adhesive bands that surround the fimbria. Gentle introduction of an alligator laparoscopic forceps into the tubal ostium followed by opening and withdrawal of the forceps helps to stretch the tube and release minor degrees of fimbrial agglutination.

46.2 In one series of 35 infertile women with severe fimbrial occlusions treated with laparoscopic fimbrioplasty, the intrauterine pregnancy rate was 51%, the live birth rate was 37%, and the ectopic pregnancy rate was 23% after 2 years follow-up.

Another study found similar outcomes after fimbrioplasty or salpingostomy: the pregnancy and fecundity rates after laparoscopic fimbrioplasty were 40% and 4%, respectively, compared to 56% and 16% following salpingostomy. The overall ectopic pregnancy rate was about 5%. It appears that the results of salpingostomy are equivalent to that of fimbrioplasty. The latter procedure results in more normal tubal anatomy.

47. Fluoroscopic/Hysteroscopic Selective Tube Cannulation

- 47.1** Obstruction of the fallopian tube close to its insertion into the uterus, which is conventionally termed "proximal," is the most treatable because it often occurs because of the accumulation of mucus or debris, which forms an impacted plug in the interstitial or proximal isthmic portion of the tube. Fallopian tube catheterization has developed as an extension of hysterosalpingography. Tubal cannulation results in improved visualization of the fallopian tube anatomy. It is also a treatment for infertility caused by proximal tubal obstruction (10%-20% of patients with tubal disease).
- 47.2** Tubal cannulation has almost eliminated the real and false diagnosis of unilateral tubal occlusion, identified patients with proximal and distal occlusion ("bipolar tubal occlusion"), and eliminated or postponed the need for a costly hysteroscopy or laparoscopy. Distal obstruction in the tube is caused by fibrosis and peritubal disease, which are not amenable to catheter recanalization techniques.
- 47.3** The procedure should not be performed if catheterization is unlikely to be successful, such as patients with Müllerian anomaly, cornual fibroids, or severe salpingitis isthmica nodosa (SIN). Both wire recanalization and balloon tuboplasty yield 80%-90% tubal patency, and 40%-50% 6-month pregnancy rates in selected patients. In summary, the tubal cannulation and easy to perform coaxial system allows versatile diagnosis and treatment of cornual tubal occlusion, as well as isthmic tubal obstruction.
- 47.4** Occlusion that develops more distally in the isthmus, or in the ampullary or fimbriated portions of the tube is commonly due to previous pelvic infection or endometriosis. It is more difficult to recanalize and patients are less likely to have a successful intrauterine pregnancy. To estimate the potential impact of fallopian tube recanalization (FTR) depends on the percentage of cases in which the occlusion is proximal. Early figures ranged between 20%-25%, meaning that the number of potentially treatable patients in the U.S. may be as high as 230,000. However, since the overall incidence of tubal disease in the 2 populations is similar (219 patients or 44%), the implication is that the number of treatable patients in the U.S. may be only 140,000 or less.
- 47.5** There is no agreement between gynecologists and radiologists regarding the proper sequence for diagnosing and treating obstructed fallopian tubes, nor is there a consensus within either of those 2 disciplines. There are also no established reporting standards, so it is difficult to make accurate comparisons between techniques, success rates, and treatment strategies. Pregnancy rates vary widely among authors, not so much because of differences in technique, but because of how the results are reported.

48. Gamete Intrafallopian Transfer (GIFT), Pronuclear Stage Transfer (PROST), or Natural Cycle IVF

48.1 The GIFT procedure is also called pronuclear stage transfer (PROST), or natural cycle IVF. In GIFT, the egg cells are retrieved laparoscopically and transferred to the fallopian tubes using a catheter containing 2-3 egg cells and approximately 100,000 sperm. Unfertilized oocytes are mixed with sperm and transferred back into the tubes. Fertilization occurs in the body as in unassisted reproduction, as compared to IVF in which fertilization occurs outside the body. Indications for GIFT are the same as for IVF, except that the woman must have 1 patent fallopian tube. Reported pregnancy rates are comparable to those associated with IVF.

48.2 In vitro fertilization (IVF) refers to a procedure designed to overcome infertility and produce a pregnancy as a direct result of the intervention. In general, the ovaries are stimulated by a combination of fertility medications and then 1 or more oocyte(s) are aspirated from ovarian follicles. These are fertilized in the laboratory ("in vitro"), after which, 1 or more embryo(s) are transferred into the uterine cavity. These steps occur over about a 2 week interval of time, which is called an IVF cycle.

48.3 The first pregnancy after the fertilization of a human egg in vitro and the first birth from an in vitrofertilized embryo were reported more than 2 decades ago. Since then, a few million pregnancies have been achieved worldwide by IVF and its modifications known generically as assisted reproductive technologies (ARTs). As experience has accumulated, success rates have increased, and the indications for these procedures have expanded, ART now accounts for 1%-3% of live births in the United States and Europe.

48.4 A complete infertility evaluation should be performed on both partners prior to embarking on IVF.

48.5 The initial experience with IVF involved women with tubal disease that could not be surgically corrected. With its efficacy established, IVF has been made available to women with other causes of infertility.

48.6 Indications for IVF include:

- a) Tubal factor
- b) Ovulatory dysfunction (after failing treatment with less invasive therapies)
- c) Diminished ovarian reserve
- d) Endometriosis (after failing treatment with less invasive therapies)
- e) Severe male factor infertility
- f) Ovarian failure
- g) Unexplained infertility (after failing treatment with less invasive therapies)

48.7 The use of IVF in these subgroups of patients is discussed in detail in the individual topics reviews listed above.

48.8 Disadvantages of IVF include the high cost, the need for procedures and drugs associated with some risk to the woman, an increased rate of multiple gestations (which accounts for much of the direct cost of pregnancies conceived via IVF, and possibly a slight increase in fetal complications. Therefore, alternative treatment options, including observation, should be considered when counseling women with open fallopian tubes and without severe male factor infertility. Although such women may have some indications for IVF (e.g., pelvic disease, endometriosis,

unexplained fertility, failed gonadotropin/ intrauterine insemination therapy), they also have substantial treatment-independent pregnancy rates.

48.9 In young women, treatable causes of subfertility should be treated prior to initiating IVF because treatment may enhance the likelihood of natural conception. In general, in the absence of absolute impediments for conception (blocked fallopian tubes, severe male factor), couples may be offered 3-6 cycles of superovulation and intrauterine insemination (IUI) before proceeding to IVF. A reasonable course when counseling young couples with no clear block to conception is to complete a total of 1 year of unprotected intercourse and 1 year of conventional treatment, since conception is quite likely during this time (about 85% conceive during the first year and a further 50% during the second year). A shorter period is generally used in older couples, as conventional treatment is less successful and time plays a much greater role in the probability of conception. It is not unreasonable to offer IVF as a primary treatment option to couples with the female partner over 40 years of age.

49. In Vitro Fertilization with Embryo Transfer (IVF-ET)

49.1 The technique of IVF-ET is now being widely used to treat infertility. Although the method was originally restricted to women who had no functioning oviducts as a result of severe tubal disease, it is now being used for women with severe endometriosis and couples with male factor or unexplained infertility. Because the rate of pregnancy after IVF is directly related to the number of embryos placed in the uterine cavity, nearly all IVF clinics currently utilize some form of ovarian hyperstimulation to increase the number of oocytes obtained at the time of follicle aspiration. Stimulation protocols utilizing clomiphene citrate, HMG or FSH, or a combination of agents are being used. These agents are usually given after a period of suppression with a GnRH agonist. GnRH antagonists are increasing being used only at mid-cycle, particularly in older women with poor responses. Monitoring of follicle growth is usually performed by both daily ultrasonography and estrogen measurement.

49.2 A few hours after egg retrieval, sperm that has been separated from semen are added to the culture medium. About 18 hours later the oocytes are observed to determine if fertilization has occurred. The oocytes that are fertilized are then cultured for an additional 48-96 hours, and from 1-4 normally cleaving embryos are then placed into the uterus of the patient in a sterile environment without the use of general anesthesia. Embryo placement is performed through a small catheter placed through the cervical canal. With the development of sequential culture media it has become possible to allow embryos to develop in vitro to the blastocyst stage, 5 days after fertilization, prior to transfer into the endometrial cavity. Several centers report per cycle pregnancy rates of 40%-60% with blastocyst culture and transfer. Most centers are freezing the embryos not utilized and transferring them in subsequent spontaneous ovulatory cycles, if pregnancy does not occur in the initial treatment cycle.

50. Intracytoplasmic Sperm Injection (ICSI)

50.1 ICSI is a laboratory procedure developed to assist couples who are undergoing IVF for severe male factor infertility. The ICSI procedure is used in conjunction with

IVF, GIFT and zygote intrafallopian transfer (ZIFT). This procedure has replaced 2 previously developed micromanipulation techniques, partial zona dissection (PZD) and subzonal insertion (SUZI) because it achieves higher fertilization rates. ICSI involves the injection of a single sperm directly into the cytoplasm of an oocyte. Several studies have demonstrated efficacy and short-term safety of ICSI.

50.2 It should be noted that in the United States, the reported risk of multiple gestations after ICSI is 30%-35% for twin gestations and 5%-10% for triplet or higher-order gestations. Some conditions may carry an increased risk for transmission of genetic abnormalities to offspring via ICSI. Whether the increased prevalence is related to the procedure or to the characteristics of couples who require ICSI is unclear. Genetic counseling may be appropriate in selected cases.

51. Low Tubal Ovum Transfer (LTOT)

51.1 A partial alternative to IVF, the ovum is aspirated from the dominant follicle during laparoscopy immediately preceding the expected time of ovulation, and injected back into the lumen of the fallopian tube above the utero-tubal junction (for upper tubal obstruction). After being mated, high number of pregnancies prevailed, thereby preserving the efficiency and safety inherent to in vivo fertilization.

52. Lysis of Adhesions

52.1 Pregnancy can occur in women with periadnexal adhesions, but the pregnancy rate appears to be higher in those who undergo adhesiolysis. In the only controlled study examining this issue, salpingo-ovariolysis was performed in 69 infertile women with pelvic adhesions, while 78 women with a similar degree of adhesions were not treated. The cumulative pregnancy rate at 24 months follow-up was significantly higher in treated women, 45% vs. 16% in the untreated group. Although adhesiolysis was done at laparotomy, equivalent results can be expected with laparoscopic adhesiolysis.

53. Myomectomy

53.1 Myomectomy is the surgical removal of fibroids from the uterus. It allows the uterus to be left in place and, for some women, makes pregnancy more likely than before. Myomectomy is the preferred fibroid treatment for women who want to become pregnant. After myomectomy, chances of pregnancy may be improved but are not guaranteed.

53.2 Before myomectomy, shrinking fibroids with gonadotropin-releasing hormone analogue (GnRH-a) therapy may reduce blood loss from the surgery. GnRH-a therapy lowers the amount of estrogen the body makes. If patients have bleeding from a fibroid, GnRH-a therapy can also improve anemia before surgery by stopping uterine bleeding for several months.

54. Ovarian Drilling and Wedge Resection

54.1 The traditional surgical treatment for PCOS was ovarian wedge resection. The procedure was performed by excising approximately one third of the ovary via laparotomy. In an initial series of 108 patients undergoing bilateral ovarian wedge resection, regular menstrual cyclicity was restored in 95% of patients, with a pregnancy rate of 85%. Subsequent reports confirmed the benefits of the

procedure, with varying rates of success. However, it became clear that wedge resection was often associated with development of periadnexal adhesions, thus obviating the beneficial effects of surgery. Ovarian wedge resection can also be performed laparoscopically. One small series of 25 patients reported a pregnancy rate of 60%; however, 36% of patients developed postoperative adhesions, again negating some of the benefits of the surgery. In addition, ovarian resection, whether performed laparoscopically or by laparotomy, is associated with substantial tissue loss. Instances of premature ovarian failure have been described, rendering the procedure obsolete by any approach.

54.2 Laparoscopic ovarian drilling is a modification of the ovarian wedge resection. Multiple holes are made on the surface of the ovary using either laser or electrocautery. This results in a decrease in circulating androgen levels, with resumption of cyclic ovulation.

55. Ovulation Induction Medications

55.1 Ovulatory disorders can be identified in the woman in 18%-25% of couples presenting with infertility. Most of these women have oligomenorrhea, arbitrarily defined as menstruation that occurs at intervals of 35 days to 6 months. While ovulation may occasionally occur, spontaneous conception is unlikely.

55.2 Induction of ovulation in these women is aimed at inducing monofollicular development, subsequent ovulation and ultimately pregnancy and birth of a healthy newborn. Induction of ovulation should be differentiated from stimulation of multiple follicle development in ovulatory women, as is done with assisted conception techniques.

55.3 The mechanism of action of antiestrogens is unclear. These agents are thought to occupy estrogen receptors in the hypothalamus and pituitary, thereby blocking the negative feedback action of estradiol. Thus, the main mechanism appears to be a rise in serum FSH concentrations by around 50%, resulting in stimulation of follicle growth and follicular estradiol production. However, other mechanisms, such as induced changes in the insulin-like growth factor system and SHBG levels, may also contribute.

56. ANTIESTROGEN THERAPY

56.1. Clomiphene citrate (CC) is the most widely used antiestrogen for ovulation induction and is most effective in normogonadotropic anovulatory women.

56.2. Correction of hyperinsulinemia with metformin has been shown to have a beneficial effect in anovulatory women with PCOS by increasing menstrual cyclicity and improving spontaneous ovulation. However, it does not appear to improve live birth rates.

56.3. Aromatase inhibitors (Letrozole and anastrozole) are a class of drugs that block the conversion of testosterone and androstenedione to estradiol and estrone, respectively (unlike clomiphene which blocks estrogen action), thereby reducing negative estrogenic feedback at the pituitary. In contrast to CC, they appear to be free of the adverse effects on endometrial and cervical mucus attributed to clomiphene citrate.

57. GONADOTROPIN THERAPY

- 57.1** Since their introduction into clinical practice in 1961, gonadotropins extracted from the urine of postmenopausal women (human menopausal gonadotropins [hMG]), in which the ratio of LH to FSH bioactivity is 1:1, have assumed a central role in ovulation induction. Refinement of the initially crude preparation resulted in the availability of purified and highly purified urinary FSH. Since 1996, recombinant human FSH (rFSH, > 99% purity) has been available. Recombinant preparations are appealing due to their ease of administration (subcutaneous rather than intramuscular).
- 57.2** The aim of ovulation induction with gonadotropins, as with clomiphene, is the formation of a single dominant follicle. In spontaneous cycles, this is achieved at the beginning of the cycle by a transient increase in serum FSH concentrations above the threshold value. The concentrations then decrease, preventing more than 1 follicle from undergoing pre-ovulatory development. Because ovarian sensitivity to FSH stimulation varies among individual women, specific treatment and monitoring protocols are needed to achieve development of a single follicle when exogenous gonadotropin is administered.
- 57.3** In the conventional gonadotropin protocol, the starting dose of FSH is 150 int. units/day. However, this regimen is associated with a multiple pregnancy rate of up to 36% and ovarian hyperstimulation occurs in up to 14% of treatment cycles.
- 57.4** In patients with PCOS, who are at particular risk for complications, this approach has been largely abandoned in favor of a low-dose, step-up protocol designed to allow the FSH threshold to be reached gradually, minimizing excessive stimulation and therefore the risk of development of multiple follicles. In this protocol, the initial subcutaneous or intramuscular dose of FSH is 37.5-75 int. units/day; the dose is increased only if, after 14 days, no response is documented on ultrasonography and serum estradiol monitoring. Increments of 37.5 int. units then are given at weekly intervals up to a maximum of 225 int. units/day. Other clinicians choose to increase the FSH dose if there is no ovarian response after 5-7 days. The optimal interval for increasing the dose has not been well studied in PCOS patients.
- 57.5** The detection of an ovarian response is an indication to continue the current dose until human chorionic gonadotropin (HCG) can be given to trigger ovulation.
- 57.6** The low-dose step-down protocol of ovulation induction mimics more closely the physiology of normal cycles. Therapy with 150 int. units FSH /day is started shortly after spontaneous or progesterone induced bleeding and continued until a dominant follicle (> 10 mm) is seen on transvaginal ultrasonography. The dose is then decreased to 112.5 int. units/day followed by a further decrease to 75 int. units/day 3 days later, which is continued until HCG is administered to induce ovulation. The appropriate starting dose can be determined by using the low-dose step-up regimen for the first treatment cycle.
- 57.7** The degree to which the type of FSH compound employed may influence outcome of ovulation induction remains the subject of controversy. Two meta-analyses comparing the effectiveness of daily urinary FSH (uFSH) to daily human menopausal gonadotropin (HMG) for inducing ovulation in women with PCOS who had not responded to clomiphene citrate demonstrated no difference in pregnancy rate per treatment cycle. However, the women given FSH were less likely to have ovarian hyperstimulation syndrome.

57.8 In a meta-analysis of randomized controlled trials comparing recombinant human FSH (rhFSH) with uFSH for ovulation induction in women with clomiphene citrate-resistant PCOS, no significant differences were demonstrated for the ovulation rate (OR 1.19; 95% CI 0.78-1.80). Furthermore, the odds ratios for pregnancy rate (0.95; 95% CI 0.64-1.41), miscarriage rate (1.26; 95% CI 0.59-2.70), multiple pregnancy rate (0.44; 95% CI 0.16-1.21) and for ovarian hyperstimulation syndrome (1.55; 95% CI 0.50-4.84) showed no significant difference between rhFSH and uFSH.

57.9 Purified urinary FSH has some LH activity, but rFSH does not. The experience with rFSH in hypogonadotropic hypogonadal women indicates that those women who have very low serum LH concentrations (<0.5 int. units/L) need exogenous HCG (or 75 int. units/day sc recombinant LH) to maintain adequate estradiol biosynthesis and follicle development.

57.10 Long-acting recombinant FSH preparations are currently being studied, but are not yet commercially available.

57.11 Human chorionic gonadotropin (HCG) is used to trigger ovulation when the ovarian follicles are mature. Both urinary and recombinant HCG preparations are available. A dose of 250 mcg of recombinant HCG appears to be equivalent to the standard doses of urinary HCG (5,000-10,000 units).

57.12 Dopamine agonist drugs enhance the tonic suppression of prolactin synthesis and release from the pituitary, substituting for or supplementing endogenous dopamine. Bromocriptine, the first dopamine agonist drug to prove effective in the treatment of hyperprolactinemia, remains in widespread use. Drugs that bind more specifically to dopamine D2 receptors on the lactotroph cells, such as cabergoline are associated with fewer side effects. The safety of bromocriptine with regard to teratogenesis is much better established than that of cabergoline, so many physicians and patients prefer bromocriptine to attempt pregnancy, but patients who have severe side effects from bromocriptine prefer cabergoline.

57.13 However, cabergoline has been associated with a dose-dependent increase in valvular heart disease. Although most cases have occurred in patients taking high dose cabergoline for Parkinson's disease, long-term use of relatively low doses for hyperprolactinemia may also be associated with excess risk.

58. Ovulation Monitoring Studies

58.1 For couples pursuing pregnancy, the highest probability of conception appears to be with intercourse 1-2 days prior to ovulation. Therefore, attempting to identify the fertile period and timing intercourse during this interval maximizes the probability of conception. This can be inferred by comparing the results of the following studies: the first series consisted of 100 fertile couples who conceived without timed intercourse and reported pregnancy rates of 50% at 3 months, 75% at 6 months, and over 90% at 12 months. Whereas a second series of similar couples who used a method of fertility awareness with timed calendar and basal body temperature (BBT) methods, are not very reliable for identifying the fertile period because of normal variation in cycle length and because the temperature rise associated with ovulation occurs too late to be useful. Better alternatives are methods that have the woman examine her vaginal discharge for changes suggestive of a preovulatory

estrogen effect, such as an increased volume of clear, stretchy, slippery mucus. Measurement of urinary luteinizing hormone is more expensive, but also effective.

58.2The LH surge can be detected in either urine or serum samples. The LH surge appears in the urine within 12 hours after it appears in the serum; as a result, it can accurately predict ovulation and therefore the optimal time for intercourse. The rise in serum LH typically occurs approximately 36 hours before the oocyte is released from the follicle into the fallopian tube. Women typically begin testing their urine 1 or 2 days before the expected surge, so that the increase over baseline levels can be clearly observed.

58.3Electronic monitors have been developed, which monitor both the estradiol and LH rise in urine to predict ovulation more precisely.

58.4Any condition associated with elevated LH levels, such as polycystic ovary syndrome, premature ovarian failure, and menopause, can yield false positive results despite the absence of ovulation. Patients should be instructed in correct use of the kit as false positive interpretation of the LH surge occurs in 7% of cycles.

59. Salpingectomy

59.1There are several methods for total laparoscopic salpingectomy. One approach is to bring the fallopian tube through a pre-tied surgical loop using a grasping forceps and 2-3 laparoscopy ports. The knot is tightened and a second loop is similarly placed. The tube can then be resected and removed.

59.2Alternatively, electrosurgery can be used to fulgurate vessels in the mesosalpinx followed by resection of the specimen with scissors. The cornual portion of the tube is desiccated close to the uterus. It is important to elevate the tube when applying electrocautery to avoid inadvertently damaging the ovarian vessels. A partial or segmental salpingectomy can also be done.

59.3Laparotomy is rarely performed due to the widespread acceptability of laparoscopy. Total salpingectomy is accomplished by placing a clamp across the mesosalpinx and then placing a second clamp across the proximal portion of the fallopian tube as close as possible to the cornua. The tips of the clamps should touch to completely occlude the vessels in the mesosalpinx. The tube is then excised and the pedicles ligated using a 2-0 or 3-0 synthetic absorbable suture.

59.4If the tubal damage is confined to the tubal segment containing the ectopic gestation, a partial salpingectomy can be performed. The clamps are placed proximal and distal to the ectopic gestation.

59.5The decision for partial vs. total salpingectomy depends on the patient's age and desire to conceive. In general, we perform partial salpingectomy to allow the option for tubal anastomosis at a future date. However, in women who will undergo IVF treatment, we prefer total salpingectomy to decrease the possibility of tubal stump pregnancy.

60. Salpingostomy

60.1Linear salpingostomy is the standard approach for management of ectopic pregnancy in women who wish to preserve their fertility. The ectopic pregnancy is identified and the tube is immobilized with laparoscopic forceps. A 22-gauge needle is inserted through a 5 mm portal and used to inject a solution of vasopressin (0.2

IU/mL of physiologic saline) into the wall of the tube at the area of maximal distention; this helps to minimize bleeding at the salpingostomy site. Using laser, unipolar needle electrocautery, ultrasonic cutting and coagulation device, or scissors, a 10-15 mm longitudinal incision is then made along the antimesenteric border overlying the ectopic. The products of conception are released from the tube using a combination of hydrodissection with irrigating solution under high pressure and gentle blunt dissection with a suction irrigator. The specimen can then be grasped with 10 mm claw forceps to remove it from the abdominal cavity; a laparoscopic pouch is useful for removal of large fragments of placental tissue.

60.2 The tube is carefully irrigated and inspected under water for hemostasis. Bleeding points can be controlled by pressure or coagulated with light application of bipolar coagulation. In order to avoid excessive coagulation to the tube, we use a microbipolar forceps. If bleeding persists, vessels in the mesosalpinx can be ligated with 6-0 polyglactin suture.

60.3 The placental bed inside the tube should not be coagulated because this will seriously damage the tube. The incision is left open to heal by secondary intention; the subsequent rates of fertility and adhesion formation are similar after secondary intention or primary closure.

61. Septate Uterus Repair

61.1 Hysteroscopic metroplasty has become the method of choice for repair of most uterine septa. Benefits to the transcervical approach include less morbidity, no abdominal or transmyometrial incisions, and faster return to normal activity. As there is no abdominal incision, possible infections and intraabdominal adhesions that may cause future infertility problems or pain are avoided. Women may attempt pregnancy sooner after a vaginal/transcervical approach than after abdominal procedures. Vaginal delivery is not contraindicated.

62. Zygote Intrafallopian Transfer (ZIFT)

62.1 A technique in which a woman's egg is fertilized outside the body, then implanted in 1 of her fallopian tubes. First, the egg and the male sperm needed to fertilize it are harvested. Then the egg and the sperm are united in a petri dish, a multi-purpose glass or plastic container with a lid. If all goes well, the sperm fertilizes the egg, and the physicians then implant it in a fallopian tube. From there, nature takes its course, and the egg eventually is deposited by the fallopian tube into the uterus (womb) for development.

62.2 A zygote is the combined cell resulting from the union of sperm and egg. A zygote develops into an embryo. An embryo, a mass of cells with no recognizable human features, begins formation of a human body.

63. Fertility Treatments for Males

64. Electroejaculation

64.1 This technique is used in patients with complete absence of antegrade ejaculation as well as a fructosenegative, sperm-negative, nonviscous postorgasmic urinalysis, usually in patients with spinal cord injury. This procedure involves use of a rectal

probe to stimulate the perirectal, periprostatic sympathetic nerves electrically. Patients without a spinal cord injury or those with low or incomplete spinal cord lesions will require general anesthesia.

65. Excision of Tumors (e.g., epididymal, spermatocele, etc.)

65.1 Obstructions that inhibit the delivery of sperm may be caused by benign tumors and cysts. A spermatocele is a benign cystic accumulation of sperm that arises from the head of the epididymis. Although often disconcerting to the patient when noticed, these lesions are benign. Spermatoceles can develop in varying locations, ranging from the testicle itself to locations along the course of the vas deferens.

Nevertheless, in common usage, spermatoceles are intrascrotal, paratesticular cystic collections of sperm that arise from the epididymis.

65.2 Most surgeries to excise tumors or cysts are aimed at testis-sparing surgeries through laparoscopic and microscopic techniques.

66. Microsurgical Epididymal Sperm Aspiration (MESA)

66.1 This technique is appropriate for men who have an epididymal or vasal obstruction. Microsurgical epididymal sperm aspiration enables the surgeon to collect large numbers of motile sperm for cryopreservation. The disadvantage of this method is that it involves a surgical procedure requiring an operating microscope and consequently increases the cost for a couple who also require IVF-ICSI.

67. Orchiopexy

67.1 An undescended testis sometimes escapes detection until adulthood. If the contralateral testis is normal, these men are likely to be fertile. If both testes are truly undescended, infertility is very likely, with most of the patients being azoospermic. Bilateral orchiopexy in adults can result in induction of spermatogenesis and pregnancy, and preserves testicular hormonal function.

68. Percutaneous Epididymal Sperm Aspiration (PESA)

68.1 Sperm are aspirated through a butterfly needle that is placed into the caudal portion of the epididymis. This method of obtaining sperm for cryopreservation or fresh IVF-ICSI is relatively quick and inexpensive compared with microsurgical open aspiration.

69. Androgens

69.1 Exogenous androgen treatment for male infertility is not indicated. Historically, androgens were among the first empiric treatments for idiopathic male infertility, based on the premise that raising serum testosterone levels would improve epididymal maturation and boost spermatogenesis. Another rationale for the use of androgens is the so-called “rebound phenomenon.” Exogenous testosterone inhibits the HPG axis and results in azoospermia; a transient increase in gonadotropins upon stopping testosterone administration has been observed.

69.2 A third hypothetical potential benefit of testosterone administration has been in the treatment of men who have androgen insensitivity. The resistance of these patients could be overcome with higher circulating testosterone levels. No data suggest this treatment approach is effective. More than 11 randomized, controlled trials have

evaluated whether androgen therapy improves pregnancy rates. Testosterone enanthate, testosterone undecanoate or mesterolone (orally active dihydrotestosterone derivative) were used in these trials. Liu and Handelsman performed a metaanalysis pooling data from 10 of these studies involving more than 1,000 men and found no improvement in pregnancy rate with androgen therapy (OR, 1.09; 95% CI, 0.73–1.62). Two prior meta-analyses also did not demonstrate efficacy of androgens for idiopathic infertility. Available evidence strongly argues against any role of androgen monotherapy for idiopathic male infertility.

70. Corticosteroids

70.1 Corticosteroids have been the most commonly employed medications used to attempt to suppress antisperm antibody formation. In some patients, corticosteroid treatment may result in improved fertility; however, this does not occur in the majority of patients.

71. Human Chorionic Gonadotropins (HCG)

71.1 Sperm production cannot be stimulated in men who are infertile as a result of primary hypogonadism (due to damage to the seminiferous tubules). However, sperm production can usually be stimulated to a level sufficient to restore fertility in men who are infertile as a result of secondary hypogonadism, i.e., due to damage to the pituitary or hypothalamus. Men who have pituitary disease can be treated with gonadotropins, while those with hypothalamic disease can be treated with gonadotropins or gonadotropin-releasing hormone (GnRH).

Secondary hypogonadism is associated with decreased secretion of the gonadotropins, luteinizing hormone (LH) and folliclestimulating hormone (FSH), resulting in reductions in testosterone secretion and sperm production.

71.2 Gonadotropin treatment of men with hypogonadotropic hypogonadism results in the appearance of sperm in the ejaculate in up to 90% of these men, but often not to normal. Even if pregnancy does not occur spontaneously, the number of sperm is often sufficient that pregnancy can be achieved with the help of an assisted reproductive technique.

72. Human Menopausal Gonadotropin (HMG)

72.1 Human menopausal gonadotropin (HMG) contains FSH and is the pharmaceutical preparation used to replace FSH in stimulating spermatogenesis in men who are infertile due to secondary hypogonadism. FSH appears to be necessary for the initiation of spermatogenesis, but not for its maintenance or re-initiation.

73. Pulsatile Gonadotropin-releasing Hormone

73.1 Gonadotropin-releasing hormone (GnRH) is administered in a pulsatile fashion by a pump and syringe that is programmed to deliver a bolus of GnRH every 2 hours and is connected to a subcutaneous needle. The apparatus is worn continuously until pregnancy occurs. The rationale for this treatment is that replacement of GnRH in a physiologic manner, in pulses every 2 hours, will stimulate the gonadotroph cells of the pituitary to secrete LH and FSH, which in turn will stimulate the testes to produce testosterone and sperm. Sperm may appear in the ejaculate as soon as 12 months after the initiation of treatment but more often 3 years or more are required.

74. Repair of Varicocele

74.1 A varicocele is a dilation of a vein (like a varicose vein) in the scrotum. Many men with varicocele have a low sperm count or abnormal sperm morphology (shape). The reason a varicocele affects the sperm may be related to a higher than normal temperature in the testicles, poor oxygen supply, and poor blood flow in the testes.

74.2 Varicocele can be treated surgically by cutting the veins connected to the varicocele. However, surgery does not always improve fertility and is not recommended for most men unless there is a large varicocele. A varicocele that has been present for a long time can cause irreversible damage that cannot be surgically treated.

74.3 Seminal Tract Washout (STW) is a technique involving the cannulation of the vas deferens and subsequent antegrade washing of the vas with collection of sperm from the bladder. STW may be used in situations where male infertility is due to incomplete voiding of the distal seminal tract, and spermatozoa can be retained downstream of the epididymis. Common conditions include diabetes, spinal cord injury, and extended retroperitoneal lymph node dissection.

75. Testicular Fine Needle Aspiration (TFNA)

75.1 The technique of testicular fine-needle aspiration (TFNA) of the testis was initially described as a diagnostic procedure in azoospermic men. Subsequently, testicular fine needle aspiration or biopsy for the recovery of spermatozoa has been described. Percutaneous puncture and aspiration of the testis can be performed using a 21-23-gauge needle connected to a 20cc syringe in a Menghini syringe holder. Percutaneous testicular needle biopsy can be performed with an automatic biopsy gun. The limited published experience to date with TFNA makes critical evaluation of this technique difficult, although it is evident from our experience that 1) sperm retrieval is routinely possible with TFNA for men with obstructive azoospermia, 2) occasional hematoceles and hematomas are possible with this technique.

75.2 The advantages of percutaneous aspiration techniques are that they can be performed with local anesthesia, without open scrotal exploration and its attendant postoperative discomfort, and without microsurgical expertise.

76. Testicular Sperm Aspiration (TESA)

76.1 Testicular sperm aspiration (TESA) is a needle biopsy of the testicle. It is an office procedure performed under local anesthesia. A small incision is made in the scrotal skin and a spring loaded needle is fired through the testicle. While it is possible to retrieve sperm using this technique, the amount is often low because the needle cuts a thin sliver of tissue. Many embryologists find this small amount of tissue difficult to work with and do not get enough sperm to freeze for future use.

77. Testicular Sperm Extraction (TESE)

77.1 Testicular sperm extraction (TESE) is an open procedure performed under direct vision and therefore minimizes potential complications. A small piece of testicular tissue is removed through a ½ inch skin incision. The tissue is placed in culture media and morselized into tiny pieces. Sperm are liberated from within the seminiferous tubules (picture to the right) where they are produced and are then extracted from the surrounding testicular tissue. This can be an exhaustive process depending on the degree of sperm production.

78. Transurethral Resection of the Ejaculatory Ducts (TURED)

78.1 Transurethral resection of the ejaculatory ducts (TURED) is the primary treatment of ejaculatory duct obstruction. A 24 French resectoscope is placed into the urethra, and resection is carried out at the level of the verumontanum. An O'Connor drape is used with a finger in the rectum to allow better depth perception and visualization of the posterior prostate. If an ejaculatory duct cyst is present, it is usually deep and just posterior to the verumontanum. Therefore, the verumontanum is deeply resected with care not to injure the rectum. Real-time ultrasonography can be used concurrently to visualize the resection of the ejaculatory cyst. Once efflux from the ejaculatory ducts of copious cloudy material or indigo carmine, if present, is identified, the resection is complete. If the cyst still is not unroofed, a Collings knife is used to make bilateral incisions just lateral to the base of the resected verumontanum. These incisions make it possible to open obstructed ejaculatory ducts that may have been missed during the initial midline incision. Electrocautery is used judiciously to avoid occlusion of the newly opened ejaculatory ducts.

79. Vasal Sperm Aspiration

79.1 Vasal aspiration is an easy procedure requiring only local anesthetic. Those with an obstructed vas deferens or who have had a vasectomy within 5 years are candidates for this procedure. A syringe is inserted into the vas deferens and the liquid inside is removed. The vas deferens is massaged in order to produce more liquid. Recovery time is generally 1 day. This is the only surgical sperm retrieval procedure that retrieves mature sperm.

Applicable Coding

CPT Codes

80414	Chorionic gonadotropin stimulation panel; testosterone response. This panel must include the following: Testosterone (84403 x 2 on 3 pooled blood samples)
80415	Chorionic gonadotropin stimulation panel; estradiol response. This panel must include the following: Estradiol (82670 x 2 on 3 pooled blood samples)
80426	Gonadotropin releasing hormone stimulation panel. This panel must include the following: Follicle stimulating hormone (FSH) (83001 x 4) Luteinizing hormone (LH) (83002 x 4)
82157	Androstenedione
82160	Androsterone
82397	Chemiluminescent assay (AMH)
82627	Dehydroepiandrosterone-sulfate (DHEA-S)*
82670	Estradiol*
82757	Fructose, semen

83001	Gonadotropin; follicle stimulating hormone (FSH)/(CCCT?)*
83002	Gonadotropin; luteinizing hormone (LH)*
83491	Hydroxycorticosteroids, 17- (17-OHCS)*
83498	Hydroxyprogesterone, 17-d*
84144	Progesterone (Progesterone challenge?)*
84402	Testosterone; free*
84403	Testosterone; total*
88248	Chromosome analysis for breakage syndromes; baseline breakage, score 50-100 cells, count 20 cells, 2 karyotypes (eg, for ataxia telangiectasia, Fanconi anemia, fragile X)*
88261	Chromosome analysis; count 5 cells, 1 karyotype, with banding*
88262	Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding*
88263	Chromosome analysis; count 45 cells for mosaicism, 2 karyotypes, with banding*
88280	Chromosome analysis; additional karyotypes, each study*
88283	Chromosome analysis; additional specialized banding technique (eg, NOR, C-banding)*
89260	Sperm isolation; simple prep (eg, sperm wash and swim-up) for insemination or diagnosis with semen analysis
89261	Sperm isolation; complex prep (eg, Percoll gradient, albumin gradient) for insemination or diagnosis with semen analysis
89300	Semen analysis; presence and/or motility of sperm including Huhner test (post coital)
89310	Semen analysis; motility and count (not including Huhner test)
89320	Semen analysis; volume, count, motility, and differential
89321	Semen analysis; sperm presence and motility of sperm, if performed
89322	Semen analysis; volume, count, motility, and differential using strict morphologic criteria (eg, Kruger)
89325	Sperm antibodies
89329	Sperm evaluation; hamster penetration test (culture) (sperm penetration assay [SPA])
89330	Sperm evaluation; cervical mucus penetration test, with or without spinnbarkeit test
89331	Sperm evaluation, for retrograde ejaculation, urine (sperm concentration, motility, and morphology, as indicated)

Female Procedures

49320	Laparoscopy, abdomen, peritoneum, and omentum, diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)*
58140	Myomectomy, excision of fibroid tumor(s) of uterus, 1 to 4 intramural myoma(s) with total weight of 250 g or less and/or removal of surface myomas; abdominal approach*
58145	Myomectomy, excision of fibroid tumor(s) of uterus, 1 to 4 intramural myoma(s) with total weight of 250 g or less and/or removal of surface myomas; vaginal approach*
58146	Myomectomy, excision of fibroid tumor(s) of uterus, 5 or more intramural myomas and/or intramural myomas with total weight greater than 250 g, abdominal approach*
58322	Artificial insemination; intra-uterine
58340	Catheterization and introduction of saline or contrast material for saline infusion sonohysterography (SIS) or hysterosalpingography*
58345	Transcervical introduction of fallopian tube catheter for diagnosis and/or reestablishing patency (any method), with or without hysterosalpingography*
58350	Chromotubation of oviduct, including materials
58540	Hysteroplasty, repair of uterine anomaly (Strassman type)
58545	Laparoscopy, surgical, myomectomy, excision; 1 to 4 intramural myomas with total weight of 250 g or less and/or removal of surface myomas*
58546	Laparoscopy, surgical, myomectomy, excision; 5 or more intramural myomas and/or intramural myomas with total weight greater than 250 g*
58555	Hysteroscopy, diagnostic (separate procedure)*
58558	Hysteroscopy, surgical; with sampling (biopsy) of endometrium and/or polypectomy, with or without D & C*
58559	Hysteroscopy, surgical; with lysis of intrauterine adhesions (any method)*
58560	Hysteroscopy, surgical; with division or resection of intrauterine septum (any method)
58561	Hysteroscopy, surgical; with removal of leiomyomata*
58562	Hysteroscopy, surgical; with removal of impacted foreign body*
58563	Hysteroscopy, surgical; with endometrial ablation (eg, endometrial resection, electrosurgical ablation, thermoablation)*
58578	Unlisted laparoscopy procedure, uterus*

58660	Laparoscopy, surgical; with lysis of adhesions (salpingolysis, ovariolysis) (separate procedure)*
58673	Laparoscopy, surgical; with salpingostomy (salpingoneostomy)
58700	Salpingectomy, complete or partial, unilateral or bilateral (separate procedure)*
58740	Lysis of adhesions (salpingolysis, ovariolysis)*
58760	Fimbrioplasty
58770	Salpingostomy (salpingoneostomy)
58920	Wedge resection or bisection of ovary, unilateral or bilateral*
58974	Embryo transfer, intrauterine
58976	Gamete, zygote, or embryo intrafallopian transfer, any method
74740	Hysterosalpingography, radiological supervision and interpretation
76830	Ultrasound, transvaginal*
76831	Saline infusion sonohysterography (SIS), including color flow Doppler, when performed*
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete*
76857	Ultrasound, pelvic (nonobstetric), real time with image documentation; limited or follow-up (eg, for follicles)
84830	Ovulation tests, by visual color comparison methods for human luteinizing hormone
88273	Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)*
89253	Assisted embryo hatching, microtechniques (any method)
89255	Preparation of embryo for transfer (any method)
89258	Cryopreservation; embryo(s)
89264	Sperm identification from testis tissue, fresh or cryopreserved
89280	Assisted oocyte fertilization, microtechnique; less than or equal to 10 oocytes
89281	; greater than 10 oocytes

Male procedures

52402	Cystourethroscopy with transurethral resection or incision of ejaculatory ducts*
54500	Biopsy of testis, needle (separate procedure)*
54505	Biopsy of testis, incisional (separate procedure)*

54640	Orchiopexy, inguinal approach, with or without hernia repair*
54650	Orchiopexy, abdominal approach, for intra-abdominal testis (eg, Fowler-Stephens)*
54692	Laparoscopy, surgical; orchiopexy for intra-abdominal testis*
54699	Unlisted laparoscopy procedure, testis*
54800	Biopsy of epididymis, needle*
54830	Excision of local lesion of epididymis*
55110	Scrotal exploration*
55300	Vasotomy for vasograms, seminal vesiculograms, or epididymograms, unilateral or bilateral
55500	Excision of hydrocele of spermatic cord, unilateral (separate procedure)*
55530	Excision of varicocele or ligation of spermatic veins for varicocele; (separate procedure)*
55535	Excision of varicocele or ligation of spermatic veins for varicocele; abdominal approach*
55550	Laparoscopy, surgical, with ligation of spermatic veins for varicocele*
55870	Electroejaculation
55899	Unlisted procedure, male genital system*
74440	Vasography, vesiculography, or epididymography, radiological supervision and interpretation
76870	Ultrasound, scrotum and contents*
89257	Sperm identification from aspiration (other than seminal fluid)
76872	Ultrasound, transrectal*;
82964	Sperm identification from testis tissue, fresh or cryopreserved
89329	Sperm evaluation; hamster penetration test

** Requires an infertility diagnosis code attached with the CPT code (ICD-10 infertility codes listed below) to be considered under infertility benefit, otherwise covered as medical benefit*

HCPCS Codes

Female Procedures

S4013	Complete cycle, gamete intrafallopian transfer (GIFT), case rate
S4014	Complete cycle, zygote intrafallopian transfer (ZIFT), case rate
S4035	Stimulated intrauterine insemination (IUI), case rate
S4042	Management of ovulation induction (interpretation of diagnostic tests and studies, nonface-to-face medical management of the patient), per cycle

Male procedures

G0027	Semen analysis; presence and/or motility of sperm excluding Huhner
Q0115	Post-coital direct, qualitative examinations of vaginal or cervical mucous
S4013	Complete cycle, gamete intrafallopian transfer (GIFT), case rate
S4014	Complete cycle, zygote intrafallopian transfer (ZIFT), case rate
S4035	Stimulated intrauterine insemination (IUI), case rate
S4042	Management of ovulation induction (interpretation of diagnostic tests and studies, nonface-to-face medical management of the patient), per cycle
S4028	Microsurgical epididymal sperm aspiration (MESA)

ICD-10 Codes (*Infertility Diagnoses*)

N46.01	Organic azoospermia
N46.021	Azoospermia due to drug therapy
N46.022	Azoospermia due to infection
N46.023	Azoospermia due to obstruction of efferent ducts
N46.024	Azoospermia due to radiation
N46.025	Azoospermia due to systemic disease
N46.029	Azoospermia due to other extratesticular causes
N46.11	Organic oligospermia
N46.121	Oligospermia due to drug therapy
N46.122	Oligospermia due to infection
N46.123	Oligospermia due to obstruction of efferent ducts
N46.124	Oligospermia due to radiation
N46.125	Oligospermia due to systemic disease
N46.129	Oligospermia due to other extratesticular causes
N46.8	Other male infertility
N50.0	Atrophy of testis
N50.89	Other specified disorders of the male genital organs
N50.9	Disorder of male genital organs, unspecified
N51	Disorders of male genital organs in diseases classified elsewhere
N53.11	Retarded ejaculation
N53.14	Retrograde ejaculation
N53.19	Other ejaculatory dysfunction
N53.8	Other male sexual dysfunction
N53.9	Unspecified male sexual dysfunction
N83.311	Acquired atrophy of right ovary

N83.312	Acquired atrophy of left ovary
N83.319	Acquired atrophy of ovary, unspecified side
N83.331	Acquired atrophy of right ovary and fallopian tube
N83.332	Acquired atrophy of left ovary and fallopian tube
N83.339	Acquired atrophy of ovary and fallopian tube, unspecified side
N83.8	Other noninflammatory disorders of ovary, fallopian tube and broad ligament
N83.9	Noninflammatory disorder of ovary, fallopian tube and broad ligament, unspecified
N84.0	Noninflammatory disorder of ovary, fallopian tube and broad ligament, unspecified
N85.6	Intrauterine synechiae
N91.0	Primary amenorrhea
N91.1	Secondary amenorrhea
N91.2	Amenorrhea, unspecified
N95.9	Unspecified menopausal and perimenopausal disorder
N97.0	Female infertility associated with anovulation
N97.1	Female infertility of tubal origin
N97.2	Female infertility of uterine origin
N97.8	Female infertility of other origin
N97.9	Female infertility, unspecified
N98.1	Hyperstimulation of ovaries
Q50.01	Congenital absence of ovary, unilateral
Q50.02	Congenital absence of ovary, bilateral
Q50.32	Ovarian streak
Q50.39	Other congenital malformation of ovary
Q50.6	Other congenital malformations of fallopian tube and broad ligament
Q51.0	Agenesis and aplasia of uterus
Q51.5	Agenesis and aplasia of cervix
Q52.11	Transverse vaginal septum
Q52.120	Longitudinal vaginal septum, non-obstructing
Q52.121	Longitudinal vaginal septum, obstructing, right side
Q52.122	Longitudinal vaginal septum, obstructing, left side

Q52.123	Longitudinal vaginal septum, microperforate, right side
Q52.124	Longitudinal vaginal septum, microperforate, left side
Q52.129	Other and unspecified longitudinal vaginal septum
Q52.4	Other congenital malformations of vagina
Q52.8	Other specified congenital malformations of female genitalia
Q52.9	Congenital malformation of female genitalia, unspecified
Q55.29	Other congenital malformations of testis and scrotum
Q55.4	Other congenital malformations of vas deferens, epididymis, seminal vesicles and prostate
Q55.8	Other specified congenital malformations of male genital organs
R86.0	Abnormal level of enzymes in specimens from male genital organs
R86.1	Abnormal level of hormones in specimens from male genital organs
R86.2	Abnormal level of other drugs, medicaments and biological substances in specimens from male genital organs
R86.3	Abnormal level of substances chiefly nonmedicinal as to source in specimens from male genital organs
R86.4	Abnormal immunological findings in specimens from male genital organs
R86.5	Abnormal microbiological findings in specimens from male genital organs
R86.6	Abnormal cytological findings in specimens from male genital organs
R86.7	Abnormal histological findings in specimens from male genital organs
R86.8	Other abnormal findings in specimens from male genital organ
R86.9	Unspecified abnormal finding in specimens from male genital organs
Z31.41	Encounter for fertility testing
Z31.448	Encounter for other genetic testing of male for procreative management
Z31.89	Encounter for other procreative management
Z52.810	Egg (Oocyte) donor under age 35, anonymous recipient
Z52.811	Egg (Oocyte) donor under age 35, designated recipient
Z52.812	Egg (Oocyte) donor age 35 and over, anonymous recipient
Z52.813	Egg (Oocyte) donor age 35 and over, designated recipient
Z52.819	Egg (Oocyte) donor, unspecified
Montana SB516_Coverage for fertility preservation caused by direct or indirect iatrogenic infertility	
Applicable ICD-10 diagnosis codes – Oncology series.	
Code Range	C00-D41
Code Range	D45-D09

Code Range D37-D49

- N46.021** Azoospermia due to drug therapy
- N46.024** Azoospermia due to radiation
- N46.121** Oligospermia due to drug therapy
- N46.124** Oligospermia due to radiation
- N97.8** Female infertility of other origin
- Z31.81** Encounter for male factor infertility in female patient
- Z31.83** Encounter for assisted reproductive fertility procedure cycle
- Z31.84** Fertility sparing procedure.
- Z31.62** Encounter for fertility preservation counseling
- Z31.94** Encounter for fertility preservation procedure

Expected/allowable place of service for each diagnosis code

POS 11, 19, 22, 24

Expected/allowable procedure code for each diagnosis code

EM code range 99202-99205 New patient

EM code range 99211-99215 Established patient

- 00840** Anesthesia for intraperitoneal procedures in lower abdomen including laparoscopy; not otherwise specified
- 00922** Anesthesia for procedures on male genitalia (including open urethral procedures); seminal vesicles
- 53899** Unlisted procedure, urinary system
- 55870** Electroejaculation
- 55899** Unlisted procedure, male genital system
- 58825** Transposition, ovary(s)
- 58970** Follicle Puncture for oocyte retrieval, any method
- 76856** Ultrasound, pelvic (nonobstetric), real time with image documentation; complete
- 76948** Ultrasonic guidance for aspiration of ova, imaging supervision and interpretation
- 82670** Estradiol; total
- 83001** Gonadotropin; follicle stimulating hormone (FSH) Gonadotropin; luteinizing hormone (LH)
- 83002** Gonadotropin; luteinizing hormone (LH)
- 84144** Progesterone Gonadotropin; chorionic (hCG); quantitative
- 84702** Gonadotropin; chorionic (hCG); quantitative
- 89254** Oocyte identification from follicular fluid Semen analysis; volume, count motility and differential
- 89320** Semen analysis; volume, count motility and differential
- 99000** Handling and/or conveyance of specimen for transfer from office to a laboratory
- 99001** Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)
- 99070** Supplies and materials (except spectacles), provided by the physician or other qualified health care professional over and above those usually included with the office visit or other services rendered (list drugs, trays, supplies, or materials provided)

99078	Physician or other qualified health care professional qualified by education, training, licensure/regulation (when applicable) educational services in a group setting (eg, prenatal, obesity, or diabetic instructions)
99199	Unlisted special service, procedure or report
S4028	Microsurgical epididymal sperm aspiration (MESA)
53899	Unlisted procedure, urinary system
55899	Unlisted procedure, male genital system
89398	Unlisted reproductive medicine laboratory procedure
When provided by an allowable rendering provider specialty/taxonomy	
Urologists	208800000X
Reproductive Endocrinologists	207VE0102X
OBGYN	207V00000X

Vendors	
•	Personify
•	HPS

References	
1.	American Urological Association (AUA) and American Society for Reproductive Medicine (ASRM). October 2020. "Diagnosis and Treatment of Infertility in Men". Accessed December 5, 2020. Available at: https://www.asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/for-non-members/diagnosis-and-treatment-of-infertility-in-men-uaa-asrm.pdf
2.	Barberet J. et al. Can novel early non-invasive biomarkers of embryo quality be identified with time lapse imaging to predict live birth? Hum Reprod. 2019; 34: 1439-1449
3.	Barratt, CL, Osborn, JC, Harrison, PE, et al. (1989). The hypo-osmotic swelling test and the sperm mucus penetration test in determining fertilization of the human oocyte. Hum Reprod 4.4: 430-4
4.	Basso, O, Olsen, J, Bisanti, L, et al. (1997). Repeating episodes of low fecundability. A multicentre European study. The European Study Group on Infertility and Subfecundity. Hum Reprod 12.7: 1448-53.
5.	Berberogluligil, P, Englert, Y, Van den Bergh, M, et al. (1993). Abnormal sperm-mucus penetration test predicts low in vitro fertilization ability of apparently normal semen. Fertil Steril 59.6: 1228-32.
6.	Bolumar, F, Olsen, J, Boldsen, J. (1996). Smoking reduces fecundity: a European multicenter study on infertility and subfecundity. The European Study Group on Infertility and Subfecundity. Am J Epidemiol 143.6: 578-87.
7.	Brassard, M, AinMelk, Y, Baillargeon, JP. (2008). Basic infertility including polycystic ovary syndrome. Med Clin North Am 92.5: 1163-92, xi.
8.	Brugh, VM, 3rd, Lipshultz, LI. (2004). Male factor infertility: evaluation and management. Med Clin North Am 88.2: 367-85.
9.	Brugh, VM, 3rd, Matschke, HM, Lipshultz, LI. (2003). Male factor infertility. Endocrinol Metab Clin North Am 32.3: 689-707.
10.	Campbell, MF, Wein, AJ, Kavoussi, LR. (2007). Campbell-Walsh urology / editor-in-chief, Alan J. Wein; editors, Louis R. Kavoussi ... [et al.]. 9th ed. 4 vols. Philadelphia: W.B. Saunders.
11.	Center for Reproductive Health. (2010) Treatments for men: Percutaneous Epididymal Sperm Aspiration (PESA). Last Update: 2010. The Center for Reproductive Health. Available: http://www.reproductivehealthctr.com/treatments_for_men_pesa.htm . Date Accessed: October 4, 2010.
12.	Centers for Disease Control and Prevention (CDC) (2017) Infertility Statistics 2017. Available at: https://www.cdc.gov/nchs/fastats/infertility.htm
13.	Choksi A, Harnisch B, Honig S. What Every Provider Should Know About the 2020–2021 Updated AUA/ASRM Guidelines on Male Factor Infertility. Current Sexual Health Reports. 2022 Jun;14(2):31-

14. Definitions of Infertility and Recurrent Pregnancy Loss: a Committee Opinion. American Society for Reproductive medicine. *Fertil Steril* 2020;113:533–5.
15. Evidence-based treatments for couples with unexplained infertility: a guideline. American Society for Reproductive medicine. *Fertil Steril* 2020;113:305–22.
16. Fitzpatrick, C. (1988). Prolactin measurement in the investigation of infertility in women with a normal menstrual cycle. *Br J Obstet Gynaecol* 95.1: 104.
17. Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. *Cochrane Database Syst Rev.* 2018 May 24;5(5):CD010287. doi: 10.1002/14651858.CD010287.pub3. PMID: 29797697; PMCID: PMC6494577.
18. Glazener, CM, Kelly, NJ, Hull, MG. (1987). Prolactin measurement in the investigation of infertility in women with a normal menstrual cycle. *Br J Obstet Gynaecol* 94.6: 535-8.
19. Goldstein, SR. (2009) Saline infusion sonohysterography. 18.2. Last Update: May, 2010. UpToDate. Available: http://www.uptodate.com/online/content/topic.do?topicKey=gyn_proc/2539&source=related_link. Date Accessed: September 26, 2010.
20. Hadziselimovic, F. (2002). Cryptorchidism, its impact on male fertility. *Eur Urol* 41.2: 121-3.
21. Hatch, EE, Bracken, MB. (1993). Association of delayed conception with caffeine consumption. *Am J Epidemiol* 138.12: 1082-92.
22. Hendriks, DJ, Mol, BW, Bancsi, LF, et al. (2006). The clomiphene citrate challenge test for the prediction of poor ovarian response and nonpregnancy in patients undergoing in vitro fertilization: a systematic review. *Fertile Sterile* 86.4: 807-18.
23. Infertility workup for the women’s health specialist. ACOG Committee Opinion No. 781. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2019;133:e377–84.
24. Inoue, M, Kobayashi, Y, Honda, I, et al. (1992). The impact of endometriosis on the reproductive outcome of infertile patients. *Am J Obstet Gynecol* 167.1: 278-82.
25. Jabbour, SA. (2009) Follicle-Stimulating Hormone Abnormalities. Last Update: June 15, 2009. *Medicine*. Available: <http://emedicine.medscape.com/article/118810-overview>. Date Accessed: September 27, 2010.
26. Jain, T, Soules, MR, Collins, JA. (2004). Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening. *Fertil Steril* 82.1: 180-5.
27. Karmazyn, B. (2010). Scrotal Ultrasound. *Ultrasound Clin*.5: 61-74.
28. Katz, VL, Lentz, GM, Lobo, RA, et al. (2007). *Comprehensive Gynecology, Management of the Causes of Infertility*. Chapter 41. 5 ed. Philadelphia Mosby.
29. Klimczak A.M. et al. B-cell lymphoma 6 expression is not associated with live birth in a normal responder in vitro fertilization population. *Fertil Steril.* 2022; 117: 351-358
30. Laboratory manual of the WHO for the examination of human semen and sperm-cervical mucus interaction. (2001). *Ann Ist Super Sanita* 37.1: I-XII, 1-123.
31. Lessey, BA. (1998). Endometrial integrins and the establishment of uterine receptivity. *Hum Reprod* 13 Suppl 3: 247-58; discussion 259-61.
32. Liu, WX, Luo, MJ, Huang, P, et al. (2007). Effects of removal of necrotic blastomeres from human cryopreserved embryos on pregnancy outcome. *Cryo Letters* 28.2: 129-36.
33. Macklin, NS, Fauser, BC. (2009) Overview of ovulation induction. 18.2. Last Update: May 27, 2009. UpToDate. Available: http://www.uptodate.com/online/content/topic.do?topicKey=r_endo_f/18204&selectedTitle=1%7E150&source=search_res ult. Date Accessed: September 27, 2010.
34. Marana, R, Catalano, GF, Muzii, L. (2003). Salpingoscopy. *Curr Opin Obstet Gynecol* 15.4: 333-6.
35. Meikle, SF, Zhang, X, Marine, WM, et al. (1994). Chlamydia trachomatis antibody titers and hysterosalpingography in predicting tubal disease in infertility patients. *Fertil Steril* 62.2: 305-12.
36. Nagy, ZP, Taylor, T, Elliott, T, et al. (2005). Removal of lysed blastomeres from frozen-thawed embryos improves implantation and pregnancy rates in frozen embryo transfer cycles. *Fertil Steril* 84.6: 1606-12.
37. Norwitz, ER. (2010) Prevention of spontaneous preterm birth. 18.2. Last Update: May 21, 2010. UpToDate. Available: http://www.uptodate.com/online/content/topic.do?topicKey=pregcomp/22936&selectedTitle=1%7E150&source=search_re sult. Date Accessed: September 24, 2010.
38. Papanikolaou, EG, Vernaev, V, Kolibianakis, E, et al. (2005). Is chromosome analysis mandatory in the initial investigation of normovulatory women seeking infertility treatment? *Hum Reprod* 20.10: 2899-903.
39. Paulson, R. (2010) In vitro fertilization (IVF). 18.2. Last Update: October 16, 2008. UpToDate. Available: http://www.uptodate.com/online/content/topic.do?topicKey=wom_issu/11302&selectedTitle=2%7E132&source=search_re sult. Date Accessed: September 22, 2010.

40. Penzias A, Azziz R, Bendikson K, Cedars M, Falcone T, Hansen K, Hill M, Jindal S, Kalra S, Mersereau J, Racowsky C. Fertility evaluation of infertile women: a committee opinion. *Fertility and sterility*. 2021 Nov 1;116(5):1255-65.
41. Peters, AJ, Lloyd, RP, Coulam, CB. (1992). Prevalence of out-of-phase endometrial biopsy specimens. *Am J Obstet Gynecol* 166.6 Pt 1: 1738-45; discussion 1745-6.
42. Practice Committee of the American Society for Reproductive Medicine. Fertility evaluation of infertile women: a committee opinion. *Fertil Steril* 2021;116:1255-65.
43. Rashed, MM, Ragab, NM, Shalaby, AR, et al. (2008). Patterns of Testicular Histopathology in Men with Primary Infertility the *Internet Journal of Urology* 5.2.
44. Revised American Fertility Society classification of endometriosis: 1985. *Fertil Steril* 43.3: 351-2.
45. Riccaboni, A, Lalatta, F, Caliari, I, et al. (2008). Genetic screening in 2,710 infertile candidate couples for assisted reproductive techniques: results of application of Italian guidelines for the appropriate use of genetic tests. *Fertil Steril* 89.4: 800-8.
46. Shin, D, Lemack, GE, Goldstein, M. (1997). Induction of spermatogenesis and pregnancy after adult orchiopexy. *J Urol* 158.6: 2242.
47. Shoupe, D, Mishell, DR, Jr., Lacarra, M, et al. (1989). Correlation of endometrial maturation with four methods of estimating day of ovulation. *Obstet Gynecol* 73.1: 88-92.
48. Sigman, M, Baazeem, A, Zini, A. (2009). Semen analysis and sperm function assays: what do they mean? *Semin Reprod Med* 27.2: 115-23.
49. Smarr, SC, Wing, R, Hammond, MG. (1988). Effect of therapy on infertile couples with antisperm antibodies. *Am J Obstet Gynecol* 158.4: 969-73.
50. Snyder, PJ. (2008) Induction of fertility in men with secondary hypogonadism. 18.2. Last Update: July 25, 2008.
UpToDate.Available: http://www.uptodate.com/online/content/topic.do?topicKey=r_endo_m/5536&selectedTitle=1%7E150&source=search_result ult. Date Accessed: October 4, 2010.
51. Spira, A. (1998). The use of fecundability in epidemiological surveys. *Hum Reprod* 13.7: 1753-6.
52. Stamenov GS, Vitale SG, Della Corte L, Vilos GA, Parvanov DA, Nikolova DN, Ganeva RR, Haimovich S. Hysteroscopy and female infertility: a fresh look to a busy corner. *Human Fertility*. 2022 May 27;25(3):430-46.
53. Tulandi, T. (2009) Laparoscopic surgery for treatment of infertility in women. 18.2. Last Update: August 24, 2009. UpToDate.
Available: http://www.uptodate.com/online/content/topic.do?topicKey=gyn_surg/14581&selectedTitle=2%7E6&source=search_result#H21. Date Accessed: September 27, 2010.
54. Tulandi, T. (2010) Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility. 18.2. Last Update: January 12, 2010. UpToDate.
Available: http://www.uptodate.com/online/content/topic.do?topicKey=gyn_surg/5788&selectedTitle=1%7E19&source=search_result#H7. Date Accessed: September 27, 2010.
55. Turek, P. (2002) Diagnostic Surgery: Vasography, Seminal Vesicle Aspiration and Testis Biopsy. Last Update: September 9, 2002.
Available: http://reference.kfupm.edu.sa/content/t/u/turek_1_diagnostic_surgery_vasography 87787. pdf. Date Accessed: September 27, 2010.
56. van Noord-Zaadstra, BM, Looman, CW, Alsbach, H, et al. (1991). Delaying childbearing: effect of age on fecundity and outcome of pregnancy. *BMJ* 302.6789: 1361-5.
57. Wein, AJ. (2007). *Campbell-Walsh urology ninth edition review*. Philadelphia: Saunders/Elsevier.

Review/Revision/Approval History	
Date	Description
07/01/2024	NEW
03/30/2026	Revised and Approved by Mountain Health CO-OP Policy Committee

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult appropriate healthcare providers for medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's benefit plan, effective when services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Including or excluding a procedure, diagnosis, or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as they apply to an individual member.

Mountain Health Co-Op makes no representations and accepts no liability regarding the content of any external information cited or relied upon in this policy. Mountain Health Co-Op updates its Coverage Policies regularly and reserves the right to amend these policies and give notice per State and Federal requirements. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Mountain Health Co-Op.

"Mountain Health Co-Op" and its accompanying logo and marks are protected and registered trademarks of Mountain Health Co-Op. The content of this Service is proprietary and protected by copyright. You may access the copyrighted content of this Service only for purposes outlined in these Conditions of Use.

© CPT Only – American Medical Association